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Introduction {#sec1}
============

Embryonic stem cells (ESCs) are capable of self-renewal and differentiation into all cell types of the body, which is conferred by the coordination of key factors, including transcription factors (TFs), polycomb complexes, microRNAs, and histone modifiers ([@bib34], [@bib26]). Such factors also include ATP-dependent chromatin remodeling complexes that hydrolyze ATP to change the conformation of chromatin, thereby modulating the access of TFs to chromosomal DNA ([@bib19]). The mammalian switch/sucrose nonfermentable (SWI-SNF) complex, also called the BAF (Brg or Brahma-associated factors) complex, represents one subfamily of the ATP-dependent chromatin remodeling superfamily and forms polymorphic assemblies of up to 15 subunits with different functional specificity based on subunit composition ([@bib19]). BAF complexes have been shown to be essential for mammalian pre- to post-implantation development ([@bib16], [@bib30]),and play important roles in controlling the self-renewal and pluripotency of ESCs ([@bib16]). However, the function of only a small number of BAF complex subunits has been studied in ESCs and in the early embryo, and how BAF complexes mechanistically control cell fate decisions is not well understood.

The BAF45 subunit is encoded by a family of four genes (*BAF45a*, *BAF45b*, *BAF45c*, and *BAF45d*) that have different expression patterns ([@bib19]). These proteins contain two plant homeodomain (PHD) fingers that may target the BAF complex to genomic loci bearing specific histone marks ([@bib19]). In the mouse, *BAF45a* is essential for the maintenance of hematopoietic stem cells ([@bib22]) and for the self-renewal of neural progenitors and is replaced by *BAF45b*/*c* as neural progenitors differentiate ([@bib19]), whereas *BAF45c* is critical for heart and muscle development ([@bib23]). *BAF45d*, also called *Dpf2*, is the only ubiquitously expressed BAF45 subunit ([@bib29]) and, so far, has been implicated in the programmed cell death response after deprivation of interleukin-3 from myeloid cells ([@bib13]). However, the biochemical interaction of DPF2 with pluripotency TFs in ESCs ([@bib31], [@bib37]) suggests a function of this BAF subunit in pluripotent cells, which has not been examined to date.

Our study shows that deletion of *Dpf2* in mouse ESCs decreased their self-renewal ability and dramatically impaired their differentiation into mesoderm and endoderm while promoting neural ectoderm differentiation. The differentiation defect to meso-endoderm could be rescued by restoring *Tbx3* levels in *Dpf2*^*−/−*^ ESCs. We also found that the PRC2 complex subunit *Eed* oppositely regulates meso-endoderm differentiation compared with *Dpf2*, also by regulating *Tbx3* expression. Mechanistically, *Dpf2* and *Eed* act on two different Tbx3-controlling enhancers. We further demonstrate that *Ezh2*, another PRC2 subunit, also regulates meso-endoderm differentiation as opposed to *Dpf2* but through a distinct mechanism that involves *Nanog* suppression. Thus, our work uncovers complex mechanisms by which PRC2 subunits and the BAF subunit *Dpf2* control differentiation of ESCs.

Results {#sec2}
=======

*Dpf2* Loss Affects ESC Self-Renewal and Leads to Increased Apoptosis and Cell-Cycle Defects {#sec2.1}
--------------------------------------------------------------------------------------------

Given the previously described biochemical interaction of DPF2 with OCT4 in mouse ESCs ([@bib31], [@bib37]) and the prominent role of OCT4 as a member of the core pluripotency network ([@bib26]), we set out to study the role of *Dpf2* in ESCs. Specifically, we generated a conditional of *Dpf2* allele in ESCs by adding LoxP sites around exon 4 ([Figure S1](#mmc1){ref-type="supplementary-material"}A). 4-Hydroxytamoxifen (4-OHT) treatment of *Dpf2* ^*fl/fl*^ ESCs resulted in an out-of-frame mutation yielding a complete *Dpf2* knockout (KO) at the protein level ([Figure S1](#mmc1){ref-type="supplementary-material"}B).

We first tested the role of *Dpf2* in ESC self-renewal. Absence of *Dpf2* expression led to a decrease in colony formation ([Figure 1](#fig1){ref-type="fig"}A), suggesting an impairment of self-renewal ability. The lower colony number arising from *Dpf2*^*−/−*^ cells coincided with a small increase in apoptosis under feeder-free conditions in Lif and serum-containing medium because *Dpf2* ^*fl/fl*^ cells were more prone to apoptosis (∼27% cell death) than wild-type (WT) ESCs (∼14%) when treated with 4-OHT for 96 hr ([Figure 1](#fig1){ref-type="fig"}B). More significant cell death was also observed for *Dpf2*^*−/−*^ ESCs cultured in N2B27 medium with BMP4 and leukemia inhibitory factor (Lif) ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Additionally, *Dpf2* deletion resulted in an ∼10% increase in cells in the G2-M cell cycle phases, whereas ∼17% fewer cells were present in S phase ([Figure S1](#mmc1){ref-type="supplementary-material"}D). In addition to the decreased ability to form colonies, alkaline phosphatase (AP) staining revealed a decrease in homogeneously stained, undifferentiated colonies in *Dpf2*^*−/−*^ ESCs ([Figure 1](#fig1){ref-type="fig"}C). We conclude that increased apoptosis, changes in the cell cycle, and an impaired ability to form colonies are consequences of *Dpf2* deletion in ESCs.Figure 1Loss of *Dpf2* Affects ESC Self-Renewal and Leads to Increased Apoptosis and Cell-Cycle Defects(A) Quantification of a colony-formation assay for WT, *Dpf2*^*fl/fl*^, and *Dpf2*^*−/−*^ mouse ESCs. Given is the mean of three replicates and the SD. ^∗∗∗^p \< 0.001.(B) Representative fluorescence-activated cell sorting (FACS) plots of Annexin V and 7-aminoactinomycin D (7-AAD) levels in *Dpf2*^*fl/fl*^ and WT control ESCs. Percentages of cells with different apoptosis marker levels are indicated in brackets.(C) Alkaline phosphatase (AP) staining assay for *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs. Colonies were scored as undifferentiated (undiff), mixed, and differentiated (diff). The mean and SD of three replicates is displayed. ^∗^p \< 0.05, ^∗∗^p \< 0.01.(D) Transcript levels of pluripotency-associated genes in *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs based on qPCR.(E) Western blot for OCT4, SOX2, NANOG, and TBX3 protein levels in *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs; α-TUBB served as a loading control.(F) Schematic of the affinity purification of FLAG-tagged DPF2 in ESCs and the MS procedure.(G) DPF2-interacting proteins annotated in the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database. Subunits of the BAF (blue), NuRD (tan), MCM (green), and MSH complexes (yellow) are highlighted.(H) GO term and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment of DPF2-interacting proteins. Selected terms are shown. FDR, false discovery rate.

*Dpf2* deletion had no effect on core pluripotency regulators such as *Oct4* and *Sox2* both at the transcript and protein levels ([Figures 1](#fig1){ref-type="fig"}D and 1E), indicating that the self-renewal defects observed in *Dpf2*^*−/−*^ ESCs were not associated with precocious differentiation. However, *Nanog* expression decreased slightly at both the transcript and protein levels, and the expression of other pluripotency regulators, including *Tbx3*, *Klf4*, and *Klf5*, was significantly decreased ([Figures 1](#fig1){ref-type="fig"}D and 1E). Previous reports have demonstrated the importance of *Tbx3* for the maintenance of ESC self-renewal ([@bib18]) and the ability of *Klfs* to support ESC self-renewal ([@bib14]), suggesting that the action of DPF2 on these genes could be critical for ESC self-renewal.

To explore the molecular mechanisms of *Dpf2* in ESCs, we fused an affinity purification (FTAP) tag ([@bib2]) to the C terminus of one endogenous *Dpf2* allele in ESCs ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F) and, after cross-linking of cells with formaldehyde to stabilize transient interactions, performed affinity purification of DPF2-containing protein complexes, followed by mass spectrometry ([Figure 1](#fig1){ref-type="fig"}F), and confirmed the results with immunoprecipitation followed by western blotting. We identified 80 high-confidence DPF2 interaction partners ([Table S1](#mmc2){ref-type="supplementary-material"}; [Figure 1](#fig1){ref-type="fig"}G), including several components of the BAF complex (BRG1 \[SMARCA4\], ARID1A, BAF155 \[SMARCC1\], BAF57 \[SMARCE1\], and BAF170 \[SMARCC2\]) ([Figure S1](#mmc1){ref-type="supplementary-material"}G), corroborating that DPF2 is a subunit of the BAF complex in ESCs. Gene ontology (GO) analysis of the DPF2 interactome revealed a significant association with proteins that exhibit chromatin-regulatory functions, including the nucleosome remodeling deacetylase (NuRD) complex ([Figure 1](#fig1){ref-type="fig"}H). In agreement with the cell cycle defect in *Dpf2*^*−/−*^ ESCs, DPF2 associated with proteins implicated in regulation of the cell cycle and DNA replication initiation ([Figures 1](#fig1){ref-type="fig"}G and 1H), including most subunits of the mini chromosome maintenance (MCM) complex, which controls DNA replication ([@bib12]), suggesting that *Dpf2* (and the BAF complex) may affect the ESC cell cycle by regulating the interaction of the MCM complex with DNA replication origins.

*Dpf2* Deletion Alters ESC Differentiation {#sec2.2}
------------------------------------------

Because KO of *Dpf2* altered the expression of some pluripotency regulators, we examined the global gene expression changes upon *Dpf2* deletion in ESCs by RNA sequencing (RNA-seq). We identified 383 significantly down- and 753 upregulated genes when comparing *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs ([Figure S2](#mmc1){ref-type="supplementary-material"}A; [Table S2](#mmc3){ref-type="supplementary-material"}). *Dpf2* loss led to the downregulation of genes associated with stem cell maintenance, blastocyst formation, and signaling pathways that control pluripotency and, in agreement with an increase in apoptosis, induced the upregulation of genes associated with cell death and negative regulation of proliferation ([Figure 2](#fig2){ref-type="fig"}A). Interestingly, we identified a number of differentiation-associated GO terms for both down- and upregulated genes in *Dpf2* KO ESCs ([Figure 2](#fig2){ref-type="fig"}A), suggesting a role of *Dpf2* in controlling differentiation pathways.Figure 2*Dpf2* Deletion Impairs ESC Differentiation(A) GO analysis for biological processes associated with genes differentially expressed upon *Dpf2* deletion in ESCs.(B) qPCR analysis for transcript levels of the indicated lineage-specific genes on days 4 and 7 of EB differentiation of *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ cells.(C) Global gene expression profiles of *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ EBs. Neuro, neural ectoderm markers; Meso, mesoderm markers; Endo, endoderm markers; Pluri, pluripotency-associated genes.(D) Images of H&E-stained teratomas from *Dpf2*^*fl/fl*^ ESCs. Magnification, 630×.(E) As in (D), except for *Dpf2*^*−/−*^ ESCs. Magnification, 200×.(F) qPCR analysis for transcript levels of the indicated lineage-specific genes in day 6 EBs from *Dpf2*^*fl/fl*^, *Dpf2*^*−/−*^, and *Dpf2*^*−/−*^ with ectopically (exo) expressed *Tbx3*.

To examine the differentiation potential of *Dpf2*^*−/−*^ ESCs, we performed embryoid body (EB) differentiation assays and assessed the expression level of well-established lineage markers. The transcript levels of the endoderm markers *Gata4*, *Gata6*, and *Sox17* and the mesoderm marker *Brachury* (*T*) were significantly lower in *Dpf2*^*−/−*^ EBs cultured for 4 or 7 days compared with their respective controls ([Figure 2](#fig2){ref-type="fig"}B), suggesting that deletion of *Dpf2* leads to impaired endoderm and mesoderm differentiation. The expression of the ectoderm marker *Fgf5* was lower in *Dpf2*^*−/−*^ EBs on day 4 but similar in WT and *Dpf2*^*−/−*^ EBs cultured for 7 days ([Figure 2](#fig2){ref-type="fig"}B). Conversely, the expression of the neural ectoderm marker *Pax6* was upregulated throughout EB differentiation, indicating that *Dpf2* loss promoted neural ectoderm differentiation ([Figure 2](#fig2){ref-type="fig"}B). We also induced ESC differentiation with retinoic acid (RA), which promotes differentiation into primitive endoderm ([@bib9]). Immunostaining against SOX17, GATA6, and GATA4 in *Dpf2*^*−/−*^ RA-differentiated cells revealed the reduction of these markers compared with WT cells, indicating that differentiation to primitive endoderm is significantly impaired without *Dpf2* ([Figure S2](#mmc1){ref-type="supplementary-material"}B).

To gain more insights into the differentiation bias of *Dpf2*^*−/−*^ ESCs, we examined the global gene expression profile of *Dpf2*^−/−^ EBs and corresponding WT controls. On day 4, a few marker genes for endoderm and mesoderm showed decreased expression and some neural-related genes showed increased expression in mutant EBs compared with controls ([Figure 2](#fig2){ref-type="fig"}C, left; [Table S3](#mmc1){ref-type="supplementary-material"}). These differences were even more pronounced in EBs on day 7, when endoderm and mesoderm-related genes showed significantly decreased and neuron-related genes increased expression in *Dpf2*^*−/−*^ EBs ([Figure 2](#fig2){ref-type="fig"}C, right; [Table S3](#mmc1){ref-type="supplementary-material"}).

To investigate the effects of *Dpf2* deletion on differentiation *in vivo*, we assayed *Dpf2*^*−/−*^ and *Dpf2*^*fl/fl*^ ESCs for their ability to form teratomas. *Dpf2*^*fl/fl*^ ESCs formed well-differentiated teratomas containing cells of all three germ layers ([Figure 2](#fig2){ref-type="fig"}D). Conversely, *Dpf2*^*−/−*^ ESCs formed mostly immature teratomas containing mostly immature neural ectoderm tissue (with prominent neuroepithelial rosettes) and trophoblast giant cells with minimal endoderm- and mesoderm-related tissues ([Figures 2](#fig2){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}C). Thus, deletion of *Dpf2* alters the differentiation propensity of ESCs *in vitro* and *in vivo*, away from meso-endoderm toward immature neural ectoderm.

To validate that the impaired differentiation phenotype was caused by deletion of the *Dpf2* gene, we asked whether overexpression of FLAG-tagged *Dpf2* rescued the defects ([Figure S2](#mmc1){ref-type="supplementary-material"}D). *Dpf2* overexpression in *Dpf2*^*fl/fl*^ ESCs before disruption of the endogenous *Dpf2* alleles did not affect self-renewal or differentiation ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F). However, when endogenous *Dpf2* was deleted in *Dpf2* ^*fl/fl*^ ESCs by 4-OHT, *Dpf2* overexpression rescued the differentiation defects of all three lineages, restoring the levels of lineage-specific markers to WT levels ([Figure S2](#mmc1){ref-type="supplementary-material"}G).

Specificity of *Dpf2* Function in ESC Differentiation {#sec2.3}
-----------------------------------------------------

In addition to *Dpf2* (*BAF45d*), *BAF45a* is expressed in mouse ESCs, whereas *BAF45b* and *BAF45c* are lowly expressed ([@bib19]). To examine whether the differentiation defect observed upon the *Dpf2* deletion is specific for *Dpf2*, we generated *Dpf2*^*fl/fl*^ ESC lines overexpressing *BAF45a* and *BAF45c* ([Figure S2](#mmc1){ref-type="supplementary-material"}H). Overexpression of either subunit prior to the deletion of *Dpf2* did not alter the expression of pluripotency and differentiation marker genes ([Figures S2](#mmc1){ref-type="supplementary-material"}I--S2L). *BAF45a* or *BAF45c* overexpression did not rescue the differentiation defects toward endoderm, mesoderm, and neural ectoderm of cells lacking endogenous *Dpf2* ([Figure S2](#mmc1){ref-type="supplementary-material"}M). These results indicate that the BAF45 subunits are not functionally redundant and highlight a specific role of *Dpf2* in lineage specification from ESCs.

*Tbx3* Rescues the Meso-endoderm Differentiation Defects of *Dpf2*^−/−^ ESCs {#sec2.4}
----------------------------------------------------------------------------

*Tbx3* was one of the pluripotency genes most affected by deletion of *Dpf2* in undifferentiated ESCs ([Figure 1](#fig1){ref-type="fig"}E). Considering the requirement of *Tbx3* for meso-endoderm differentiation ([@bib40], [@bib39]), we hypothesized that *Dpf2* may control the differentiation potential of ESCs via regulation of *Tbx3* expression. To test this idea, we stably transfected FLAG-tagged *Tbx3* into *Dpf2*^*fl/fl*^ cells and subsequently deleted *Dpf2*. The data show that the endoderm marker genes *Gata4*, *Gata6*, *Sox17*, and *Pdgfra* reached nearly WT levels in *Dpf2*^−/−^ 4-day and 6-day EBs ectopically expressing *Tbx3* ([Figures 2](#fig2){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}N). Similarly, ectopic *Tbx3* expression restored the expression levels of the mesoderm marker genes *T*, *Bmp4*, *Gata2*, and *Hand1* in *Dpf2*^*−/−*^ 6-day EBs ([Figures 2](#fig2){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}N). Conversely, the increase in neural ectoderm markers (*Pax6*, *Nes*, and *Tubb3*) observed in *Dpf2*^−/−^ EBs was not reduced by Tbx3 overexpression ([Figures 2](#fig2){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}N). We conclude that overexpression of *Tbx3* rescued the endoderm and mesoderm differentiation defects induced by loss of *Dpf2* and that the enhancement of neural-ectoderm differentiation in *Dpf2*^*−/−*^ EBs did not occur through regulation of *Tbx3*.

Because *Tbx3* overexpression itself promotes endodermal and mesodermal genes in differentiating ESCs ([@bib40]), it remained possible that *Tbx3* expression may upregulate endo- and mesodermal genes in cells that have differentiated toward neuroectoderm upon Dpf2 deletion. To exclude this possibility, we performed immunofluorescence staining of GATA4 in combination with NESTIN and TUBB3 in differentiating *Dpf2*^*−/−*^ cells expressing *Tbx3* exogenously and found that cells expressed GATA4 in the absence of the neuroectoderm markers ([Figures S2](#mmc1){ref-type="supplementary-material"}O and S2P). Thus, in the absence of *Dpf2*, *Tbx3* overexpression induces faithful differentiation toward endodermal and mesodermal lineages.

DPF2 Co-occupies Active Enhancers with OCT4, SOX2, and BRG1 in ESCs {#sec2.5}
-------------------------------------------------------------------

To understand how *Dpf2* regulates *Tbx3*, we profiled the genome-wide binding sites of DPF2 in ESCs using chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) ([Table S4](#mmc4){ref-type="supplementary-material"}). We found that the majority of DPF2 binding events occurred at genomic locations distal to transcriptional start sites (TSSs), including both intergenic regions and gene bodies ([Figure 3](#fig3){ref-type="fig"}A). By intersecting DPF2-bound genomic locations with previously annotated ESC chromatin states ([@bib10]), we found that DPF2 predominantly binds enhancers, particularly those with high levels of the histone marks H3K27ac, H3K4me2, and H3K4me1, characteristic of the most active enhancers ([Figure 3](#fig3){ref-type="fig"}B, states 3 and 4). GO analysis indicated that DPF2-occupied sites are located close to genes associated with functions in stem cell maintenance, morphogenesis, gastrulation, and development ([Figure 3](#fig3){ref-type="fig"}C).Figure 3DPF2 Associates with Active Enhancers and the Oct4, Sox2, and Brg1 Network in ESCs(A) Distribution of DPF2 target sites determined by ChIP-seq in ESCs in relation to their distance to TSSs.(B) Chromatin state enrichment of DPF2 target sites in ESCs. ESC chromatin states were defined in [@bib10] using ChromHMM. Rows represent chromatin states and their mnemonics. Columns give the frequency of the indicated histone marks and H3.3 for each chromatin state (ChromHMM emission probabilities), color-coded from blue (highest) to white (lowest). Enrichment of DPF2 in each chromatin state is shown in the last column.(C) Significant GO terms for genes with DPF2 target sites within 10 kb of their TSS.(D) Motifs identified at DPF2-bound sites by *de novo* search and the best matching TFs.(E) Hierarchical clustering of pairwise enrichments of DPF2, BRG1, OCT4, SOX2, NANOG, ESRRB, KLF4, EED, and EZH2 binding sites in ESCs. BRG1 and EED binding sites were identified from *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESC lines, and all other binding events were obtained from WT ESCs. The black box indicates highest correlation enrichment for pairwise binding.(F) Heatmaps of normalized ChIP-seq signal for Dpf2, Brg1, Oct4, Sox2, Nanog, and p300 at all sites bound by DPF2 in ESCs.(G) Genome browser view of DPF2, BRG1, OCT4, SOX2, NANOG, and P300 binding at the *Nanog* locus in ESCs.(H) Heatmaps of normalized ChIP-seq signal for Dpf2 and Brg1 at BRG1 occupied sites in *Dpf2*^*fl/fl*^ or *Dpf2*^−/−^ ESC lines.

To gain insights into the determinants of DPF2 binding, we searched for sequence elements enriched within DPF2 target sites. We found motifs for the Klf and Tead family members Esrrb, Nanog, and Sox2 as well as the Oct-Sox composite site to be most enriched ([Figure 3](#fig3){ref-type="fig"}D), suggesting that DPF2 is bound at sites engaged by the core pluripotency TFs. This result was corroborated by comparing the binding profile of DPF2 with those of Oct4, Sox2, Nanog, Klf4, and Esrrb genome-wide ([Figures 3](#fig3){ref-type="fig"}E and 3F) and at the *Nanog* locus as an example ([Figure 3](#fig3){ref-type="fig"}G). Among these pluripotency TFs, DPF2 binding sites overlapped more often with those of Oct4 and Sox2 than with those of Nanog, Esrrb, and Klf4 ([Figure 3](#fig3){ref-type="fig"}E). In agreement with previous data showing that DPF2 is a component of the OCT4 protein network ([@bib37], [@bib31]), we confirmed the interaction of the two proteins by co-immunoprecipitation ([Figure S3](#mmc1){ref-type="supplementary-material"}A) and found that 48.5% of all OCT4 binding events were co-occupied by DPF2.

Additionally, we performed ChIP-seq for BRG1, the ATPase subunit of the BAF complex, and found a high overlap of DPF2 and BRG1 genome occupancy, consistent with mass spectrometry (MS) ([Figure 1](#fig1){ref-type="fig"}G) and immunoprecipitation data for DPF2 ([Figure S3](#mmc1){ref-type="supplementary-material"}B) and the notion that DPF2 mainly acts as a subunit of the BAF complex in ESCs ([Figures 3](#fig3){ref-type="fig"}E-H). As expected from the localization of DPF2 to active enhancers ([Figure 3](#fig3){ref-type="fig"}B), we also detected an extensive co-localization of DPF2 with the transcriptional co-activator P300 ([Figures 3](#fig3){ref-type="fig"}E-3G). The significant co-binding between DPF2 and P300 was further supported by the physical interaction observed between DPF2 and P300 in co-immunoprecipitation experiments ([Figure S3](#mmc1){ref-type="supplementary-material"}C). DPF2 binding did not extensively overlap with that of EED and EZH2, subunits of the repressive polycomb complex PRC2 ([Figures 3](#fig3){ref-type="fig"}E, [S3](#mmc1){ref-type="supplementary-material"}D, and S3E). Together, these findings reveal collaboration with pluripotency TFs at enhancers and suggest that *Dpf2* plays a role in the selection and activation of enhancers in ESCs.

*Dpf2* Loss Does Not Globally Affect the Binding of BRG1 and PRC2 {#sec2.6}
-----------------------------------------------------------------

To determine whether *Dpf2* deletion globally affects the binding of BRG1, we performed ChIP-seq for BRG1 in ESCs after *Dpf2* deletion. *Dpf2* loss did not prevent binding of BRG1, which maintained a similar genome-wide binding profile as in WT *Dpf2*^*fl/fl*^ ESCs ([Figures 3](#fig3){ref-type="fig"}E, 3H, and [S3](#mmc1){ref-type="supplementary-material"}D). This result suggests that the BAF complex assembly remains unperturbed at the vast majority of its physiological targets in the absence of *Dpf2*. Similarly, *Dpf2* loss did not affect the binding profile of the PRC2 subunit EED at the genome-wide level ([Figure S3](#mmc1){ref-type="supplementary-material"}E), consistent with their largely non-overlapping binding sites ([Figure 3](#fig3){ref-type="fig"}E).

*Dpf2* Depletion Modulates H3K27ac Levels and Binding of OCT4 and BRG1 {#sec2.7}
----------------------------------------------------------------------

Given the gene expression changes observed by the absence of *Dpf2*, we investigated whether DPF2 engages genes that become deregulated in KO ESCs. We found that ∼63% of the differentially expressed genes in *Dpf2*^*−/−*^ ESCs associated with a DPF2 binding event within 20 kb around their TSSs ([Figure 4](#fig4){ref-type="fig"}A; 719 of 1,136 genes, p \< 0.0001, chi-square test), including both up- and downregulated genes, suggesting that *Dpf2* can activate and repress gene expression. Pluripotency genes downregulated in the absence of *Dpf2*, including *Klf4*, *Klf5*, and *Tbx3,* were direct binding targets of DPF2 ([Figure 4](#fig4){ref-type="fig"}A).Figure 4*Dpf2* Depletion Modulates Levels of H3K27ac and OCT4(A) Heatmap of expression levels (log~2~RPKM+1) in *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs for differentially expressed genes between *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs and their DPF2 binding based on a DPF2 peak within 10 kb of the TSS (red, bound; black, unbound genes).(B) Number of genomic sites with a significant change in H3K27ac (\>2-fold difference) between *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs, divided into those with a reduction (top) and increase (bottom) in *Dpf2*^*−/−*^ ESCs, and their association with DPF2 in WT ESCs.(C) Heatmap of normalized tag density profiles of H3K27ac experiments in *Dpf2*^*fl/fl*^*and Dpf2*^*−/−*^ cells at sites with significant H3K27ac changes from (B).(D) Metaplots of average signal intensities for H4tetrac, H3K9ac, H3K4me1, H3K27me3, OCT4, SOX2, and P300 at DPF2-bound sites in ESCs with reduced (top) or increased (bottom) H3K27ac, as defined in (B), for *Dpf2*^*fl/fl*^ (blue) and *Dpf2*^*−/−*^ ESCs (red).(E) As in (B), but for sites with significant differences in OCT4 instead of H3K27ac.(F) Metaplots of average signal intensities for OCT4 in *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs at sites with significant OCT4 changes that are also occupied by DPF as defined in (E).(G) Heatmap of normalized tag density profiles of H3K27ac e in *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs at sites with significant OCT4 binding changes and occupied by DPF2 (E) and corresponding metaplots of signal intensities.(H) Genome browser view of ChIP-seq tracks of DPF2, BRG1, EED, and OCT4 binding as well as H3K27ac and H3K27me3 for the *Bmp4* locus. DPF2 data are from WT ESCs and the others from *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs, indicated as fl/fl and −/−. Regions highlighted in blue signify ESC enhancer regions as defined by ChromHMM in [@bib10]. The values on the y axis represent fold enrichment over control.(I) Heatmap of normalized tag density profiles of DPF2, EED, H3K27ac, and P300, at sites exhibiting a reduction in BRG1 in *Dpf2*^*−/−*^ ESCs compared with *Dpf2*^*fl/fl*^ ESCs. DPF2 data are from WT ESCs and all others from *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs, indicated as fl/fl and −/−.(J) Metaplots of average signal intensities for DPF2 and BRG1, H3K27ac, p300 and Oct4 at sites defined in (I).

We next asked how *Dpf2* affects the histone modification landscape. Hence, we generated maps for five histone modifications from *Dpf2*^*fl/fl*^ or *Dpf2*^*−/−*^ ESC lines, including H3K27ac, H3K4me1, H4-tetraAC and H3K9ac, which are associated with promoters and enhancers, and the repressive histone mark H3K27me3 ([@bib11]). We did not observe significant differences in the average H3K27ac signal between *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ cells when all DPF2 binding sites were considered ([Figure S4](#mmc1){ref-type="supplementary-material"}A). However, we identified 4,581 sites with significant reduction (≥2-fold) of H3K27ac in *Dpf2*^*−/−*^ compared with *Dpf2*^*fl/fl*^ ESCs ([Figures 4](#fig4){ref-type="fig"}B and 4C). We also observed 2,513 sites that gained H3K27ac signal by 2-fold or more upon *Dpf2* deletion ([Figures 4](#fig4){ref-type="fig"}B and 4C). 21% of sites with decreased H3K27ac levels and 46% of sites with an increase in H3K27ac were bound by DPF2 in WT ESCs ([Figure 4](#fig4){ref-type="fig"}B) and located predominantly in enhancers ([Figure S4](#mmc1){ref-type="supplementary-material"}B), indicating that *Dpf2* contributes to the regulation of H3K27ac at active enhancers in ESCs.

H3K4me1, H4-tetraAC, H3K9ac, and binding by Oct4 and Sox2 followed similar trends to H3K27ac at DPF2-occupied sites, and the repressive mark H3K27me3 exhibited an antithetical pattern ([Figure 4](#fig4){ref-type="fig"}D). P300 presence was dramatically affected at DPF2-bound sites with diminished H3K27ac levels in *Dpf2*^−/−^ ESCs but displayed very little change DPF2 sites with a gain of H3K27ac ([Figure 4](#fig4){ref-type="fig"}D). Thus, DPF2 controls the chromatin state and pluripotency TF binding at a subset of its target sites.

Given the extensive co-localization of DPF2 with OCT4 and the interaction between these two proteins, we investigated the effect of *Dpf2* loss on OCT4 binding in ESCs further. On average, OCT4 binding was not different between *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ cells at sites normally bound by DPF2 ([Figure S4](#mmc1){ref-type="supplementary-material"}C). However, a more detailed analysis identified a significant decrease of OCT4 binding at 6,082 genomic locations in cells lacking *Dpf2* expression, with 27% of those exhibiting DPF2 binding in ESCs ([Figures 4](#fig4){ref-type="fig"}E and 4F) and an accompanying reduction in H3K27ac levels in *Dpf2*^−/−^ ESCs ([Figure 4](#fig4){ref-type="fig"}G). A much smaller number of sites displayed an increase in OCT4 binding in *Dpf2*^−/−^ ESCs (737), accompanied by an increase in H3K27ac, with many bound by DPF2 in ESCs ([Figures 4](#fig4){ref-type="fig"}E--4G). As seen in our H3K27ac analysis, DPF2-bound sites with changes in Oct4 levels were more enriched in enhancers than promoters ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Interestingly, DPF2 binding sites exhibiting loss of H3K27ac and OCT4 binding, respectively, were strongly enriched close to downregulated genes ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Conversely, DPF2-bound locations at genes with elevated expression upon *Dpf2* loss were enriched for changes in H3K27ac and OCT4 binding, but less strongly ([Figure S4](#mmc1){ref-type="supplementary-material"}D). These results suggest that *Dpf2* can act as both a suppressor and activator of gene expression through the regulation of H3K27ac, P300, and OCT4 levels and that enhancers are key sites of its action.

The destabilization of OCT4 binding and reduction of H3K27ac upon loss of *Dpf2* is exemplified at enhancers within the *Bmp4* ([Figure 4](#fig4){ref-type="fig"}H), *Tbx3* ([Figure 6](#fig6){ref-type="fig"}A), *Gjb3*, Lama1,and *Nkx6-3* loci ([Figures S4](#mmc1){ref-type="supplementary-material"}E--S4G). ChIP-qPCR confirmed this result for OCT4 binding at these genes and extended the findings to P300 ([Figures S4](#mmc1){ref-type="supplementary-material"}H and S4I). Although the binding of SOX2 and NANOG at these loci also decreased ([Figures S4](#mmc1){ref-type="supplementary-material"}J and S4K), we did not detect any interaction of the DPF2 protein with either SOX2 or NANOG in co-immunoprecipitation experiments ([Figure S4](#mmc1){ref-type="supplementary-material"}L), suggesting that the loss of these TFs is due to OCT4 loss.

Even though overall BAF complex binding remained largely unaffected by the loss of *Dpf2* ([Figure 3](#fig3){ref-type="fig"}), 8% of the BRG1 sites exhibited a reduction in BRG1 occupancy and a concurrent reduction of H3K27ac, P300, and OCT4 ([Figures 4](#fig4){ref-type="fig"}I and 4J) and were located in enhancers enriched close to genes downregulated upon *Dpf2* loss ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4D). Thus, at least for a number of sites, DPF2 loss associates with the de-stabilization of the entire BAF complex in addition to the reduction of OCT4 and P300. These sites include the examples described above ([Figures 4](#fig4){ref-type="fig"}H, [S4](#mmc1){ref-type="supplementary-material"}E-S4G, and [6](#fig6){ref-type="fig"}A). The targeting of new sites by BRG1 was negligible in Dpf2^−/−^ ESCs. The impaired binding of BRG1 at only a subset of sites may be explained by the existence of multiple BAF complexes in ESCs that consist of different core components. These results confirm a role of *Dpf2* in the recruitment of OCT4 and BRG1 at a subset of sites within ESC enhancers.

DPF2 Occupancy Changes with Differentiation {#sec2.8}
-------------------------------------------

To gain mechanistic insights into the actions performed by DPF2 during differentiation, we performed ChIP-seq for DPF2 in EBs cultured for 2 or 4 days ([Table S4](#mmc4){ref-type="supplementary-material"}). DPF2 bound a large number of new genomic locations as early as 2 days post-differentiation (clusters II, III, and V) ([Figure 5](#fig5){ref-type="fig"}A). Two-thirds of ESC binding events were lost upon differentiation (clusters I and IV) and one-third was maintained (clusters VI and VII) upon differentiation ([Figure 5](#fig5){ref-type="fig"}A). ESC-specific DPF2 binding sites were located in the vicinity of genes associated with blastocyst formation and trophectoderm differentiation (cluster I; [Figure 5](#fig5){ref-type="fig"}B), whereas newly bound sites in EB-neighbored genes associated with neuronal development (clusters III and V; [Figure 5](#fig5){ref-type="fig"}B), supporting a direct role of DPF2 in the regulation of neural ectoderm differentiation. Constitutively bound DPF2 sites were associated with endodermal and mesodermal as well as notochord development (cluster VII; [Figure 5](#fig5){ref-type="fig"}B) and contained binding events in the vicinity of the endodermal and mesodermal marker genes *Gata4*, *Gata6*, *Sox17*, and *T* ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Consistent with the maintenance of *Dpf2* binding, we did not observe a change in H3K27ac levels at these sites ([Figure S5](#mmc1){ref-type="supplementary-material"}A). These data suggest that the gene expression changes in endo-mesodermal genes observed upon *Dpf2* deletion do not occur through a direct function of DPF2. Consistent with this idea, overexpression of *Dpf2* in ESCs did not lead to the upregulation of endo- and mesodermal markers ([Figure S2](#mmc1){ref-type="supplementary-material"}F).Figure 5Regulation of Meso-endoderm Differentiation by *Dpf2* and *Eed* via *Tbx3*(A) Clustering of Dpf2 binding events in ESCs and day 2 and 4 EBs. The genome was divided into 500-bp bins and a bin called bound (blue) or unbound (white) based on the presence of a DPF2 peak.(B) GO analysis for enriched biological process for genes associated with DPF2 peaks from different clusters defined in (A), within ± 20 kb of the TSS.(C) Transcript levels of the indicated endoderm markers in day 4 EBs from *Dpf2*^*fl/fl*^, *Eed*^*−/−*^, and *Eed/Dpf2* double KO determined by qPCR.(D) As in (C), except for pluripotency-associated genes in *Dpf2*^*fl/fl*^, *Dpf2*^*−/−*^, *Eed*^*−/−*^, and *Dpf2* and *Eed* double KO ESCs.(E) As in (C), except for *Tbx3* in day 4 EBs from *Dpf2*^*fl/fl*^, *Eed*^*−/−*^, and *Eed/Dpf2* double KO ESCs.(F) As in (C), except for various endoderm markers in 4-day EBs induced from *Eed*^*−/−*^ and *Eed*^*−/−*^*/Tbx3* kd ESCs.(G) As in (C), except for various mesoderm markers and *Tbx3* in day 7 EBs from *Dpf2*^*fl/fl*^, *Eed*^*−/−*^, and *Eed/Dpf2* double KO ESCs.(H) As in (C), except for various neuroectoderm markers in day 6 EBs from *Dpf2*^*fl/fl*^, *Dpf2*^*−/−*^, and *Eed/Dpf2* double KO ESCs.

*Dpf2* and *Eed* Control Meso-endoderm Differentiation by Opposingly Regulating *Tbx3* {#sec2.9}
--------------------------------------------------------------------------------------

Previous studies showed that the deletion of *Eed* increases the expression of endoderm and mesoderm markers ([@bib3], [@bib6], [@bib25]). Because we observed the downregulation of endo- and mesodermal genes in differentiating *Dpf2*^*−/−*^ ESCs ([Figure 2](#fig2){ref-type="fig"}), we hypothesized that endo- and mesoderm differentiation may be oppositely regulated by *Eed* and *Dpf2*. To test this idea, we deleted the *Eed* gene in *Dpf2*^*fl/fl*^ cells by targeting its second exon with an out-of-frame mutation leading to loss of the EED protein ([Figures S5](#mmc1){ref-type="supplementary-material"}B--S5D). Immunostaining verified the loss of H3K27me3 in *Eed*^*−/−*^ ESCs ([@bib3]; [Figure S5](#mmc1){ref-type="supplementary-material"}E). Subsequently, we induced differentiation of *Dpf2*^*fl/fl*^, *Eed*^*−/−*^, and *Eed*/*Dpf2* double KO ESCs by EB formation.

As expected, KO of *Eed* led to increased expression of the endodermal genes *Gata4*, *Gata6*, *Sox7*, and *Sox17* ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}F) ([@bib3]). The expression of these genes was restored close to WT levels in *Dpf2* and *Eed* double KO EBs ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}F), demonstrating that *Eed* and *Dpf2* regulate endoderm differentiation in an opposing manner.

Next we studied how *Eed* and *Dpf2* mechanistically regulate endoderm differentiation. Deletion of *Eed* did not dramatically affect the expression of *Oct4*, *Sox2*, and *Nanog* in ESCs but significantly increased *Tbx3* expression, contrary to the downregulation of *Tbx3* in *Dpf2*^*−/−*^ ESCs ([Figure 5](#fig5){ref-type="fig"}D). When we induced the deletion of *Dpf2* in *Eed*^*−/−*^ cells, *Tbx3* expression decreased toward WT levels ([Figure 5](#fig5){ref-type="fig"}D). We conclude that *Eed* and *Dpf2* oppositely regulate *Tbx3* expression in ESCs and during the onset of differentiation.

We further investigated whether the increase in *Tbx3* expression in the absence of *Eed* was responsible for the increase in endodermal gene expression. We found that *Tbx3* transcript levels correlated with the expression of *Gata4*, *Gata6*, *Sox7*, and *Sox17* during differentiation of *Dpf2*^*fl/fl*^, *Eed*^*−/−*^, and *Eed*/*Dpf2* double KO cells ([Figures 5](#fig5){ref-type="fig"}C, 5E, [S5](#mmc1){ref-type="supplementary-material"}F, and S5G). Therefore, we induced EB formation from *Eed*^−/−^/*Tbx3* knockdown (kd) ESCs in which *Tbx3* transcripts were depleted by RNAi-mediated knockdown ([Figure S5](#mmc1){ref-type="supplementary-material"}H). Expression of *Gata4*, *Gata6*, and *Sox7* decreased when *Tbx3* was depleted compared with *Eed*^*−/−*^ cells ([Figure 5](#fig5){ref-type="fig"}F), indicating that *Eed* controls endoderm differentiation, at least partially, via regulating *Tbx3* expression, and that the balance of *Dpf2* and *Eed* is critical for the regulation of *Tbx3*.

These conclusions extend to the regulation of mesoderm differentiation. Contrary to the downregulation of the mesoderm genes *T*, *Bmp4*, *Hand1*, and *Gata2* in differentiating *Dpf2*^*−/−*^ ESCs ([Figure 2](#fig2){ref-type="fig"}), the expression of these genes significantly increased in *Eed*^*−/−*^ EBs and was largely restored in *Dpf2* and *Eed* double KO EBs ([Figure 5](#fig5){ref-type="fig"}G). Similarly, the induced expression of the neural ectoderm markers *Nes*, *Pax6*, *Ncam1*, and *Pcdh17* observed in *Dpf2*^*−/−*^ EBs was restored to physiological levels in *Dpf2* and *Eed* double KO EBs ([Figures 5](#fig5){ref-type="fig"}H and [S5](#mmc1){ref-type="supplementary-material"}I). Thus, in addition to endoderm differentiation, *Eed* and *Dpf2* oppositely regulate mesoderm and neural ectoderm differentiation.

*Dpf2* and *Ezh2* Regulate Endo- and Mesoderm Differentiation by Regulating *Nanog* {#sec2.10}
-----------------------------------------------------------------------------------

Given that *Eed*, *Ezh2*, and *Suz12*, the core subunits of PRC2, have different effects on ESC differentiation ([@bib3], [@bib6], [@bib25]), we wanted to find out what the effects of *Ezh2* were in our system. We deleted the fifth exon of the *Ezh2* gene homozygously in *Dpf2* ^*fl/fl*^ cells, which resulted in loss of EZH2 at the protein level ([Figure S6](#mmc1){ref-type="supplementary-material"}A), and induced EB formation of *Dpf2*^*fl/fl*^, *Ezh2*^*−/−*^, and *Ezh2* and *Dpf2* double KO ESCs. In contrast to the upregulation of endoderm markers in the absence of *Eed* ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}F), KO of *Ezh2* led to repression of *Gata4*, *Gata6*, *Sox7*, and *Sox17* ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C). The expression of these genes was restored close to WT levels in *Dpf2* and *Ezh2* double KO EBs ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C), indicating that *Ezh2* and *Dpf2* regulate endoderm differentiation in an opposing manner but differently compared with *Eed*. *Ezh2* and *Dpf2* also opposingly regulated mesoderm differentiation ([Figure S6](#mmc1){ref-type="supplementary-material"}D). The decreased expression of meso-endoderm genes in *Ezh2*^*−/−*^ EBs ([Figures S6](#mmc1){ref-type="supplementary-material"}B--S6D) occurred despite an increase in *Tbx3* expression upon deletion of *Ezh2* ([Figure S6](#mmc1){ref-type="supplementary-material"}E). Thus, *Eed* and *Ezh2* both repress *Tbx3* in ESCs but have rather distinct effects on meso-endoderm differentiation.

Consistent with previous reports ([@bib33], [@bib38]), *Nanog* was upregulated in *Ezh2*^*−/−*^ ESCs ([Figure S6](#mmc1){ref-type="supplementary-material"}E). Because *Nanog* overexpression in ESCs is reported to repress endoderm and mesoderm lineages ([@bib7]), we postulated that the regulation of *Nanog* could explain the observed impairment of differentiation toward these lineages in *Ezh2*^*−/−*^ ESCs ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6D). Indeed, the expression of endo- and mesodermal genes in *Ezh2*^*−/−*^ EBs increased when *Nanog* was knocked down by short hairpin RNA (shRNA) ([Figures S6](#mmc1){ref-type="supplementary-material"}F and S6G). *Nanog* was downregulated when *Dpf2* was deleted in *Ezh2*^*−/−*^ ESCs ([Figure S6](#mmc1){ref-type="supplementary-material"}E), which may restore the differentiation of *Ezh2* and *Dpf2* double KO ESCs to mesoderm and endoderm. Furthermore, we found that neural ectoderm genes were repressed in *Ezh2*^*−/−*^ EBs, which could be restored close to WT levels upon deletion of *Dpf2* ([Figures S6](#mmc1){ref-type="supplementary-material"}H and S6I), demonstrating the opposing regulation of neural ectoderm differentiation by *Dpf2* and *Ezh2*.

Taken together, *Eed* and *Ezh2* hinder and promote meso-endoderm differentiation of ESCs, respectively. The PRC2 subunits achieve these opposing effects by acting through different downstream TFs (*Tbx3* versus *Nanog*). In contrast, during neural-ectoderm differentiation, both PRC2 subunits repress the program, suggesting that they may have the same downstream targets in this process.

*Dpf2* and *Eed* Regulate *Tbx3* through Different Enhancers {#sec2.11}
------------------------------------------------------------

Because DPF2 predominantly binds active enhancers in ESCs, we speculated that *Dpf2* regulates *Tbx3* expression by regulating H3K27ac levels at its enhancers. Indeed, we found that *Dpf2* deletion in ESCs decreased H3K27ac of the previously described intronic enhancer (IE) ([@bib4]) and a distal enhancer (DE) located about 87 kb upstream of the TSS ([Figure 6](#fig6){ref-type="fig"}A). Interestingly, *Dpf2* deletion decreased OCT4 and SOX2 binding, but only at the DE and not at the IE ([Figure 6](#fig6){ref-type="fig"}A), suggesting that the DE may be critical for the regulation of *Tbx3* by *Dpf2* in ESCs. In agreement with this, with the circular chromosome conformation capture assay (4C) using the *Tbx3* promoter as a viewpoint, the *Tbx3* promoter was found in spatial proximity to the DE in *Dpf2*^*fl/fl*^ ESCs but to the IE in *Dpf2*^*−/−*^ ESCs ([Figure 6](#fig6){ref-type="fig"}B). Moreover, deletion of the DE ([Figure S7](#mmc1){ref-type="supplementary-material"}A) significantly decreased *Tbx3* transcript levels ([Figure 6](#fig6){ref-type="fig"}C) and impaired meso-endoderm differentiation ([Figure 6](#fig6){ref-type="fig"}D). These data indicated that *Dpf2* regulates *Tbx3* expression mainly via the modulation of H3K27ac on the DE, which changes the access of OCT4 and other TFs or vice versa.Figure 6*Dpf2* and *Eed* Regulate *Tbx3* Expression by Controlling Histone Modifications and Accessibility of Pluripotency TFs at Different Enhancers(A) Genome browser view of ChIP-seq tracks for DPF2 and P300 in WT ESCs and BRG1, OCT4, SOX2, EED, H3K27ac, and H3K27me3 in *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs (indicated as fl/fl and −/−) at the *Tbx3* locus. The distal enhancer (DE) and intronic enhancer (IE) enhancers are highlighted. The values on the y axis represent fold enrichment over control.(B) Circular chromatin conformation capture (4C-seq) analysis of the *Tbx3* promoter. The arcs represent significant interactions from the *Tbx3* promoter viewpoint in *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs. The DE and IE are indicated.(C) Transcript levels of *Tbx3* in two DE KO ESC clones and control ESCs based on qPCR.(D) As in (C), except for the indicated lineage markers in day 6 EBs from WT and the two DE KO ESCs.(E) H3K27ac levels at *Tbx3* enhancers in *Dpf2*^*fl/fl*^, *Eed*^*−/−*^, and *Eed/Dpf2* double KO ESCs, determined by ChIP-qPCR.(F) As in (E), except for relative levels of EED, EZH2, and SUZ12 at the IE of the *Tbx3* gene in *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs.(G) As in (E), except for relative levels of OCT4 and SOX2 at the IE of the *Tbx3* gene in WT and *Eed*^*−/−*^ ESCs.

Considering how EED regulates *Tbx3*, we found that deletion of *Eed* did not affect the level of H3K27ac on either the IE or DE ([Figure 6](#fig6){ref-type="fig"}E). However, we identified a strong enrichment of H3K27me3 and EED at the IE and across the *Tbx3* gene in ESCs but not at the DE ([Figure 6](#fig6){ref-type="fig"}A). As expected, KO of *Eed* led to the loss of H3K27me3 at the IE ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Moreover, the deletion of *Dpf2* induced an increase of EED and H3K27me3 as well as the other two PRC2 subunits, EZH2 and SUZ12, at the IE and across the *Tbx3* gene body ([Figures 6](#fig6){ref-type="fig"}A and 6F) without a change in OCT4 and SOX2 binding at the IE ([Figure 6](#fig6){ref-type="fig"}A). Thus, *Dpf2* deletion in ESCs did not alter the accessibility of key pluripotency transcription factors but increased the access of PRC2 to the IE and across the *Tbx3* gene body. Deletion of *Dpf2* also led to decreased binding of the BRG1 on the DE region, which was not the case at the IE region because BRG1 binding was largely unaffected ([Figure 6](#fig6){ref-type="fig"}A). We also found that deletion of the IE in ESCs did not strongly affect the expression of *Tbx3* in ESCs ([Figure S7](#mmc1){ref-type="supplementary-material"}C), suggesting that the IE does not contribute to the downregulation of *Tbx3* in *Dpf2*^*−/−*^ ESCs. However, OCT4 and SOX2 binding increased at the IE in *Eed*^*−/−*^ ESCs ([Figure 6](#fig6){ref-type="fig"}G), which may provide the mechanism for how the loss of *Eed* results in upregulation of *Tbx3*. Taken together, our data indicate that *Dpf2* regulates *Tbx3* by modulating H3K27ac and binding of pluripotency TFs at the DE, whereas *Eed* controls *Tbx3* through the regulation of H3K27me3 across the gene body and pluripotency factor access at the IE, which results in opposite outcomes regarding *Tbx3* expression.

*Dpf2* and *Eed* Regulate Gene Expression Oppositely via Modulating Histone Modifications and Binding of Pluripotency TFs {#sec2.12}
-------------------------------------------------------------------------------------------------------------------------

Finally, we compared the transcription profiles of *Dpf2*^*−/−*^ and *Eed*^*−/−*^ ESCs to determine whether there are additional transcripts with similar trends as observed for *Tbx3*. We found 328 deregulated genes in both *Dpf2*^*−/−*^ and *Eed*^*−/−*^ ESCs (p \< 0.05) ([Figure S7](#mmc1){ref-type="supplementary-material"}D) and 2,482 shared target genes with both DPF2 and EED sites in their vicinity ([Figure S7](#mmc1){ref-type="supplementary-material"}E). Intersecting the two sets of genes, we identified 144 genes directly regulated by *Dpf2* and *Eed* ([Figure S7](#mmc1){ref-type="supplementary-material"}F). Among those, 34 genes were downregulated in *Dpf2*^*−/−*^ ESCs and upregulated in *Eed*^*−/−*^ ESCs, similar to the opposing regulation of *Tbx3* by *Dpf2* and *Eed* ([Figure S7](#mmc1){ref-type="supplementary-material"}G). These genes included *Bmp4*, *Sox21*, and *Lama1* ([Figures S7](#mmc1){ref-type="supplementary-material"}G and S7I) and were associated with embryonic development based on GO analysis ([Figure S7](#mmc1){ref-type="supplementary-material"}H). Similar to *Tbx3*, the respective regulation of H3K27ac and H3K27me3 by *Dpf2* and *Eed* was observed for *Bmp4*, *Sox21*, and *Lama1* ([Figures S7](#mmc1){ref-type="supplementary-material"}J and S7K). Moreover, the binding of OCT4 and SOX2 at these genes decreased in *Dpf2*^*−/−*^ ESCs ([Figures S7](#mmc1){ref-type="supplementary-material"}L and S7M) but increased in *Eed*^*−/−*^ ESCs ([Figures S7](#mmc1){ref-type="supplementary-material"}N and S7O). Thus, our study uncovered that *Dpf2* and *Eed* oppositely regulate a set of genes important for embryonic development by modulating the deposition of H3K27ac and H3K27me3 and altering the access of pluripotency TFs.

Discussion {#sec3}
==========

In this study, we revealed that the BAF subunit DPF2 is critical for ESC differentiation into mesoderm, endoderm, and neural ectoderm. Moreover, we show that meso-endoderm differentiation defects because of *Dpf2* deletion can be rescued by restoring the expression of *Tbx3* to normal levels. The differentiation defects of *Dpf2* KO ESCs are different from those described for other BAF components ([@bib16]), in agreement with the notion that different subunits confer different functionalities. Importantly, this study defines a functional downstream target of the BAF complex in ESCs, for which maintenance of expression is important for ESC fate decisions.

Our study further revealed an opposing regulation of endoderm and mesoderm differentiation by *Dpf2* and *Eed*. This relationship was supported by the restored expression of endoderm and mesoderm marker genes in *Eed*/*Dpf2* double KO EBs. We postulate that *Dpf2* and *Eed* oppositely regulate endo- and mesoderm differentiation of ESCs via differential control of *Tbx3* expression.

An antagonistic role of polycomb and BAF complexes has been reported previously through competitive binding of these complexes at the same locus ([@bib41], [@bib17], [@bib20]). In contrast, our work shows that Eed and Dpf2 function in meso-endoderm differentiation via their respective interaction at different enhancers, the IE and DE, respectively, at the *Tbx3* locus, as summarized in [Figure 7](#fig7){ref-type="fig"}. Specifically, the loss of *Eed* diminished the enrichment of H3K27me3 over the *Tbx3* gene, including its IE, which increased the access of OCT4 and SOX2 to the IE, which likely leads to upregulation of *Tbx3*. The loss of *Dpf2* led to an increase of H3K27me3 deposition at the IE of *Tbx3* by increasing the access of PRC2, consistent with competitive binding between PRC2 and BAF complexes at the IE. Conversely, the loss of *Dpf2* significantly decreased the H3K27ac level and the access of OCT4 and SOX2 at the DE. The decrease in OCT4 binding could precede the drop of H3K27ac because the impaired physical interaction of DPF2 and OCT4 upon loss of *Dpf2* may destabilize OCT4 binding. Conversely, because P300 is known to acetylate histone H3K27 ([@bib34]), another possible scenario for the decrease in H3K27ac is that loss of the direct interaction between DPF2 and P300 leads to the decrease in H3K27ac in *Dpf2*^*−/−*^ ESCs, which, in turn, may affect OCT4 binding. Regardless, the interaction between DPF2, P300, and OCT4 indicates a collaborative regulation of *Tbx3* via a chromatin remodeler, chromatin modifications, and critical TFs.Figure 7Model for the Regulation of ESC Differentiation by *Dpf2* and *Eed* via the Control of *Tbx3* Expression*Dpf2* and *Eed* regulate *Tbx3* expression via modulation of the H3K27ac level at the DE and the H3K27me3 level at the IE. Loss of *Dpf2* induces downregulation of *Tbx3* via a decrease of both H3K27ac and pluripotency TF binding on the DE, leading to impaired differentiation into meso-endoderm. In *Eed*^*−/−*^ ESCs, H3K27me3 levels decrease at the IE, whereas the binding of pluripotency TFs increases, resulting in *Tbx3* upregulation and enhanced differentiation to meso- and endoderm. In *Dpf2*^*−/−*^*/Eed*^*−/−*^ ESCs, *Tbx3* expression is restored to physiological ESC levels, as is the potential for differentiation into endo- and mesoderm.

Our study also demonstrates that the opposing regulation of targets by *Dpf2* and *Eed* in ESCs is not limited to *Eed* but extends to the PRC2 subunit Ezh2. However, meso-endoderm markers were repressed in the absence of Ezh2, in contrast to their increase upon Eed deletion. We show that these differences in the differentiation defect are achieved through distinct downstream transcription factors because the opposing effect of *Dpf2* and *Ezh2* ensued mainly via differential regulation of *Nanog*.

*Brg1* is a core unit of BAF complex and is required for the self-renewal and pluripotency of ESCs ([@bib16]). We confirmed the interaction of DPF2 and BRG1 by immunoprecipitation and showed that these proteins extensively co-localize in the genome. Although both *Brg1* and *Dpf2* positively regulate *Tbx3* expression in ESCs ([@bib17]), *Dpf2* did not affect the expression of *Oct4*, which is upregulated upon acute deletion of *Brg1* ([@bib5]), indicating that *Dpf2* mediates specific functions of the BAF complex during embryonic development. As a core factor of the BAF complex, *Brg1* likely affects embryonic development by participating in various BAF complexes with different components ([@bib16], [@bib30]). Consistent with this conclusion, loss of *Dpf2* does not dramatically alter the genome-wide binding of BRG1.

In summary, PRC2 and BAF complexes are important for the ESC differentiation and embryonic development ([@bib16]). Our study uncovered unique mechanisms by which a specific BAF subunit and PRC2 subunits regulate genes important for the ESC differentiation.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse monoclonal GAPDHAbcamab9484Rabbit polyclonal RequiemSigmaSAB4502621Mouse monoclonal FLAGSigmaF1804Rabbit polyclonal TBX3Invitrogen42-4800Goat polyclonal OCT4R&D systemsAF1759Goat polyclonal SOX2R&D systemsAF2018Mouse monoclonal NESTINBD PharMingen556309Mouse monoclonal TUBB3PromegaG712ARabbit polyclonal NANOGAbcamAb80892Mouse monoclonal P300Active motif61401Mouse monoclonal STAT3Cell Signaling Technology9139Rabbit monoclonal H3K27acAbcamab177178Rabbit polyclonal H3K27me3Millipore07449Rabbit polyclonal H3K4me3Abcamab8580Rabbit polyclonal H3K9acAbcamab4441Mouse monoclonal H4-tetraACActive motif39967Polyclonal goat SOX17R&D systemsAF1924Rabbit polyclonal GATA4Santa Cruzsc-9053Goat polyclonal GATA6R&D systemsAF1700Rabbit polyclonal SUZ12Abcamab12073Mouse monoclonal EZH2BD PharMingen612667Rabbit polyclonal EEDMillipore17-10034Rabbit monoclonal BRG1Abcamab110641Mouse IgGThermoFisherA-11032Alex488-conjugated donkey anti-goat IgGThermoFisherA-11055Alex594-conjugated donkey anti-rat IgGThermoFisherA-21209Alex488-conjugated donkey anti-mouse IgGThermoFisherA-21202Alex594-conjugated donkey anti-rabbit IgGThermoFisherA-21207DAPIThermoFisherD1306**Bacterial and Virus Strains**DH5a Competent CellsNEBC-29871One Shot TOP10 Chemically Competent *E. coli*ThermoFisherC404010**Chemicals, Peptides, and Recombinant Proteins**LIFMilliporeESG1107BMP4R&D System5020-BP-010ZeocinThermoFisherR25001G418ThermoFisher11811031PuromycinThermoFisherA1113802Protease inhibitorsRoche4693159001BenzonaseSigmaE8263-5KU2x Laemmli Sample BufferBio-Rad\#16107373X FLAG peptideSigmaF4799-4MGTrypsin-EDTA (0.25%), phenol redThermoFisher25200056ParaformaldehydeSigmaP6148-500GDisuccinimidyl glutarateThermiFisher20593Triton X-100SigmaT8787-50ML4-HydroxytamoxifenTOCRIS3412TamoxifenSigmaT5648Annexin-APCBD PharMingen5504757-AADBD PharMingen559925SYBR Green PCR Master MixThermoFisher4309155ABsolute QPCR Mix, ROXThermoFisherAB1139ASequalPrep Long PCR Kit with dNTPsThermoFisherA10498Expand Long Template PCR SystemRoche03321053103Disuccinimidyl glutarateThermoFisher20593Proteinase KThermoFisher25530049T4 DNA ligaseNEBM0202SCsp6IThermo FisherFD0214MboIThermoFD0814Vivaspin500 PES centrifugal filtersVivascienceVS0102KAPA HTP Library Preparation kitRoche07961901001**Critical Commercial Assays**AP staining kitSigmaSCR004SequalPrep Long PCR kitInvitrogenA10498BCA Protein Assya KitPierce23227ECL PlusAmershamRPN2133RNeasy mini kitQIAGEN74104TotalPrep RNA Amplification KitAmbionAMIL1791NucleoSpin gDNA Clean-Up kitMacherey-Nagel740230.10SuperscriptIII reverse transcriptaseInvitrogen18080093Click-iT EdU Pacific Blue flow cytometry Assay KitInvitrogenC10636Pierce BCA Protein Assay KitInvitrogen23225**Deposited Data**ChIP-seqThis studyE-MTAB-6165RNA-seqThis studyE-MTAB-61664CThis studyE-MTAB-6167**Experimental Models: Cell Lines**E14 ESCsThis studyN/AR26::CreERT2 - E14 ESCsThis studyN/AR26::CreERT2 Dpf2 fl/fl E14 ESCsThis studyN/AEed −/− R26::CreERT2 Dpf2 fl/fl E14 ESCsThis studyN/AEzh2 −/− R26::CreERT2 Dpf2 fl/fl E14 ESCsThis studyN/ATbx3 DE KO ESCsThis studyN/ATbx3 IE KO ESCsThis studyN/A**Experimental Models: Organisms/Strains**SCID miceHans Scholer's GroupN/A**Deposited Data**ChIP-seq dataThis studyE-MTAB-6165 (ArrayExpress)RNA-seq dataThis studyE-MTAB-6166 (ArrayExpress)4C dataThis studyE-MTAB-6167 (ArrayExpress)Proteomics dataThis studyPXD011806 (ProteomeXchange)**Oligonucleotides***Oct4*TaqManMm00658129_gH*Klf4*TaqManMm00516104_m1*Nanog*TaqManMm02384862_g1*Rex1*TaqManMm03053975_g1*Nr0b1*TaqManMm00431729_m1*Klf2*TaqManMm01244979_g1*Klf5*TaqManMm00456521_m1*Gapdh*TaqMan4352339E*Tbx3*TaqManMm01195726_m1*GATA6*TaqManMm00802636_m1*GATA4*TaqManMm00484689_m1*Sox17*TaqManMm00488363_m1*FGF5*TaqManMm00438918_m1*Sox1*TaqManMm00486299_s1*Pax6*TaqManMm00443072_m1*Brachyury*TaqManMm01318252_m1*Tubb3*TaqManMm00727586_s1*Dpf2*TaqManMm00599980_m1*Nestin*TaqManMm00450205_m1*Pdgfra*TaqManMm00440701_m1*GATA2*TaqManMm00492301_m1*Bmp4*TaqManMm00432087_m1*Hand1*TaqManMm00433931_m1*Sox21*TaqManMm00844350_s1*Gjb3*TaqManMm00433647_m1*Lama1*TaqManMm01226102_m1*Ncam1*TaqManMm01149710_m1*Pcdh17*TaqManMm00977568_m1See [Table S5](#mmc1){ref-type="supplementary-material"} for qPCR and gRNA sequencesThis StudyN/A**Recombinant DNA**Dpf2 targeting vectorEUCOMM resourceN/AC-FTAP-tag Dpf2 knockin vectorThis studyN/ApPyCAG-*Dpf2*-IZHitoshi NiwaN/ApPyCAG-*Tbx3*-INHitoshi NiwaN/ApCAGGs-FlpEThis studyN/ANanog shRNAWu QiangN/ATbx3 shRNAApril KartikasariN/A**Reagent or Resource**GMEMSigma-AldrichG2549FCSGIBCO10439024Non-essential amino acidGIBCO11140050Sodium pyruvateGIBCO113600702-mercaptoethanolGIBCO21985023L-glutamineGIBCO25030081TCEPSigma75259IodoacetamideSigmaI6125colloidal CoomassieSigmaB2025AggreWell 400 platesSTEMCELL Technoligies34421Dynabeads Protein GInvitrogen10003D4-12% Bis-Tris Novex gelInvitrogenNP0321BOXPVDF membranesBiorad1620177**Software and Algorithms**ChromHMM v1.1.0[@bib10]N/ABowtie2 v2.2.1[@bib24]N/ACufflinks v2.2.1[@bib36]N/AMACS2 v20140616[@bib42]N/ABedTools v2.27[@bib32]N/AHOMER v4.9.0[@bib15]N/AMetascape<http://metascape.org>N/AProteome Discover 1.4ThermofisherN/ATophat version 2.0.13[@bib35]N/AMascot 2.5Matrix ScienceN/A

Contact for Reagent And Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for reagents may be directed to and will be fulfilled by the Lead Contact, Wensheng Zhang (<zhangwensheng@suda.edu.cn>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell culture {#sec4.3.1}

E14 ESCs were cultured in GMEM (Sigma) supplemented with 10% FCS, 1 × NEAA, 1 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, and LIF (Millipore) on gelatin coated plates, or cultured in N2B27 medium with BMP4 (10ng/ml) and LIF.

Method Details {#sec4.4}
--------------

### Colony formation assay {#sec4.4.1}

For colony formation assays, dissociated cells with trypsin were plated at about 1,000 cells per 10cm plate. ESCs were cultured for 7 days and stained for alkaline phosphatase using the AP staining kit (Sigma). We scored colonies with ∼90% AP-positive cells as un-differentiated, colonies with ∼5% AP-positive staining cells as differentiated, and colonies of intermediate AP-positive cell number as partially differentiated.

### Teratoma formation assay {#sec4.4.2}

5 × 10^6^ cells were injected subcutaneously into the flank of SCID mice. After 4-5 weeks, teratomas were isolated, transferred into Bouin's fixative overnight and subjected to histological examination with H&E staining based on standard protocols. All tissues were examined by a board-certified anatomic pathologist (M.P.), blinded to the genotype of the ESCs.

### Generation of a conditional knockout of Dpf2 in ESCs {#sec4.4.3}

The *Dpf2* targeting vector was linearized and electroporated into R26::CreERT2 E14 cells to generate heterozygous ESC lines after G418 selection. Heterozygous ESC clones were transiently transfected with a FLP recombinase encoding plasmid (pCAGGs-FlpE), converting the initial knockout allele (*Dpf2*^*+/−*^, lacZ positive, G418 resistant) into a "wild-type" (WT) allele with two loxP sites flanking exon 4 (floxed allele) (*Dpf2*^*fl/+*^, reverted WT (rWT), lacZ negative, G418 sensitive). Multiple independent rWT ESC clones were then electroporated with the original *Dpf2* knockout vector and again selected with G418. Targeting of the second WT allele was confirmed by the presence of both the rWT allele and the second knockout allele through long-range PCR reactions (SequalPrep Long PCR kit, Invitrogen). Selected heterozygous ESC lines were converted to the conditional *Dpf2*^*fl/fl*^ state by transiently transfecting FlpE.

### Generation of Eed and Ezh2 knockout ESC clones {#sec4.4.4}

2ug of gRNA and 2ug of Cas9 plasmids were electroporated to ESCs. After 7 days' selection with 175ug/ml of G418, colonies were picked up for genotyping and confirmed by Sanger sequencing.

### Co-Immunoprecipitation (Co-IP) and Western Blotting {#sec4.4.5}

Cells were lysed in lysis buffer (1% NP40; 50mM Tris-HCl, pH7.4; 150mM NaCl; 1mM EDTA with protease inhibitors (Roche)). Protein concentrations were determined using the BCA Protein Assay Kit (Pierce). For immunoprecipitation, cell lysates were incubated with the indicated antibodies for 1 hour. Protein G-associated Dynabeads^®^ (Thermo Fisher) were added at 4°C overnight. After washing three times with lysis buffer, 1X protein SDS loading buffer (Bio-Rad) was added and boiled for 5 minutes. The supernatant was cooled on ice for 5 minutes before loading on the gel for immunoblotting. Proteins were fractionated on a 4%--12% Bis-Tris Novex gel (Invitrogen), electroblotted onto PVDF membranes, and membranes probed sequentially with respective antibodies. Blots were incubated with secondary antibodies and developed with ECL Plus (Amersham).

### Affinity purification of the DPF2 complex {#sec4.4.6}

Formaldehyde-crosslinked ESCs expressing DPF2-FTAP were used for affinity purification of DPF2, and an ESC line expressing a beta-gal-FTAP fusion protein ([@bib2]) was used as a control. Whole cell extracts were prepared using a high salt lysis buffer (450 mM NaCl, 0.2% Nonidet P-40) as previously described ([@bib31]), with several modifications. Briefly, cells were crosslinked with 1% formaldehyde for 10 minutes at room temperature; after a 10 min incubation of cells in lysis buffer on ice, 1 ul/mL of benzonase (99% purity, Sigma) was added and the cell suspension was incubated at 37°C for 15 min. The lysate was then cleared by centrifugation at 16,100 r*cf.* for 15 min at 4°C. FLAG affinity purification was essentially performed as previously described. Anti-FLAG Dynal beads were prepared by crosslinking M2 FLAG antibody (Sigma) to Protein G-Dynal beads (Invitrogen) in accordance with the manufacturer's instructions. Whole-cell extracts were incubated with anti-FLAG M2 Dynal beads in buffer containing 150 mM NaCl and 0.1% NP-40 for 90 min at 4°C. Beads were washed three times with RIPA buffer, then 3 times with RIPA buffer containing 450 mM NaCl, and once with elution buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 0.02% Nonidet P-40). Proteins were eluted in elution buffer containing 200 μg/mL 3X FLAG peptide (Sigma). Eluates were concentrated in Vivaspin500 PES centrifugal filters (10 kDa cut-off, Vivascience), reduced with 5 mM TCEP (Sigma), and alkylated with 10 mM iodoacetamide (Sigma). Samples were fractionated by polyacrylamide gel electrophoresis using Novex NuPAGE Bis-Tris 4%--12% gels (Invitrogen) and stained with colloidal Coomassie (Sigma) as previously described ([@bib31]). Full gel lanes were sliced in 7-24 bands, gel pieces were de-stained completely and digested with trypsin (sequencing grade, Roche). Peptides were extracted using 0.5% formic acid-50% acetonitrile and dried in a Speed Vac (Thermo Fisher Scientific).

### Mass spectrometry {#sec4.4.7}

Peptides were re-dissolved in 0.5% formic acid and analyzed on an Ultimate 3000 RSLCnano System (Dionex) coupled to an LTQ FT Ultra (Thermo Fisher Scientific) hybrid or Orbitrap Velos mass spectrometer equipped with a nanospray source. The peptides were first loaded and desalted on a PepMap C18 trap column (0.1 mm id x 20 mm, 5μm), then separated on a PepMap 75 μm id x 25 cm column (5μm) over a 60 min linear gradient of 4 -- 42% B / 90 min cycle time when coupled with FT Ultra, or 15 cm column over a 30 min linear gradient of 4 -- 40% B / 60 min cycle time when coupled with Orbitrap Velos, where B is 80% CH3CN/0.1% Formic Acid. The LTQ FT Ultra was operated in the "top 5" data-dependent acquisition mode with the preview mode of FT master scan enabled. The FT full scan was set at m/z 380 -- 1800 with the resolution at 100,000 at m/z 400 and AGC at 1x106 with a maximum injection time at 500 msec. The five most abundant multiply-charged precursor ions, with a minimal signal above 1000 counts, were dynamically selected for CID fragmentation (MS/MS) in the LTQ ion trap, with the AGC set at 1x104 with the maximum injection time at 200 msec. The dynamic exclusion was set at ± 20 ppm for 45 s. For analysis on the LTQ Orbitrap Velos, the mass spectrometer was operated in the "top 10" data-dependent acquisition mode with preview mode of FT master scan enabled. The Orbitrap full scan was set at m/z 380 -- 1500 with the resolution at 100,000 at m/z 400 and AGC at 1x106 with a maximum injection time at 200 msec. The 10 most abundant multiply-charged precursor ions, with a minimal signal above 2000 counts, were dynamically selected for CID fragmentation (MS/MS) in the LTQ ion trap, with the AGC set at 5000 with the maximum injection time at 100 msec. The dynamic exclusion was set at ± 10 ppm for 60 s.

### Immunofluorescence staining {#sec4.4.8}

Cells were fixed in 4% paraformaldehyde for 10 minutes at room temperature, blocked, and permeabilized with 3% serum in PBS with 0.3% Triton X-100 and then incubated with the indicated antibodies at 4°C overnight. After washing, cells were incubated with Alex594-conjugated goat anti-mouse IgG (ThermoFisher, A-11032), Alex488-conjugated donkey anti-goat IgG (ThermoFisher, A-11055) or Alex594-conjugated donkey anti-rat IgG (ThermoFisher, A-21209) and counter-stained with DAPI to detect nuclei.

### Quantitative RT-PCR {#sec4.4.9}

Total RNA was isolated with RNeasy mini kit (QIAGEN). cDNA was synthesized with Superscript III reverse transcriptase (Invitrogen). Real-time PCR was performed with TaqMan Gene Expression Assay (Applied Biosystems). Gene expression was determined relative to Gapdh transcript levels. Standard deviation was calculated from PCR triplicates. Error bars give the SD of three technical qPCR replicates from a representative experiment.

### Apoptosis Assays {#sec4.4.10}

*Dpf2*^*fl/fl*^ and WT ESCs were treated with ethanol or 0.65 μM of 4-Hydroxytamoxifen (4-OHT) for 96 hours, subsequently, cells were harvested with trypsin and washed with PBS. ESCs were then stained with Annexin-APC (BD Biosciences) and 7-AAD (BD Biosciences) according to the manufacturer's instructions (BD Biosciences) and analyzed by flow cytometry. Cells were gated and analyzed for annexin V and 7-AAD. High level of annexin V and low levels of 7-aminoactinomycin D (7-AAD) show early apoptosis in cells, whereas high levels of both annexin V and 7-AAD indicate a late stage of apoptosis. Cells were considered healthy if the levels of both annexin V and 7-ADD were low.

### Cell Cycle assay {#sec4.4.11}

*Dpf2*^*fl/fl*^ and WT E14 cells were cultured in the presence or absence of 4-OHT condition for five days before the cell cycle assay was performed. ESCs were trypsinized, re-plated and cultured in standard lif/serum ESC medium with 10uM of EdU. After incubation for 1 to 3 hours, cells were harvested for the cell cycle assay using the Click-iT^@^ EdU Pacific Blue flow cytometry Assay Kit (Invitrogen).

### Chromatin Immunoprecipitation (ChIP) coupled with Quantitative Real-Time PCR (ChIP-qPCR) {#sec4.4.12}

ChIP-qPCR was performed as previously described ([@bib8]). Briefly, ChIP experiment were performed as described below in the ChIP-seq section. After purification of the immunoprecipitated DNA, 1 μL was used per qPCR reaction. Bound regions were detected by using paired primers given in [Table S5](#mmc1){ref-type="supplementary-material"}. Real -time PCR was run using SYBR Green Mix (2x) from Applied Biosystems. Each reaction contained 10 μL 2x SYBR Green Mix, 1 μL 10 μM Primer mix, 8 μL H2O and 1 μL immunoprecipitated DNA. The program was used as follows: 98°C 5 minutes, (98°C 20 s, 60°C 30 s, 72°C 20 s) X 40. Quantitative PCR was performed at least in duplicate, from at least two independent experiments, and data were normalized to input values and calculated as percent input recovery using the ΔΔCt method.

### ChIP-seq {#sec4.4.13}

ChIP was typically performed in *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESC lines, except for DPF2, which were done in C-FTAP tag Dpf2 knockin ESCs and and EBs formed for 2 and 4 days respectively. Transcription factor and epigenetic regulator occupancy data generated in this study were acquired using ChIP after crosslinking cells. Briefly, cells were grown to a final concentration of 5x10^7^ cells for each ChIP-seq experiment. To stabilize DPF2, BRG1, P300, EED, Oct4 and Sox2 on chromatin, cells were treated with 2 mM disuccinimidyl glutarate (DSG) for 10 minutes prior to formaldehyde crosslinking. For all other targets (H3K4me3, H3K4me1, H3K27ac, H3K9ac, H4tetra-ac, H3K27me3), cells were cross-linked at room temperature by the addition of formaldehyde to 1% final concentration for 10 minutes and quenched with 0.125 M final concentration of glycine. Cross-linked cells were re-suspended in sonication buffer (50mM HEPES-KOH pH 7.5, 140mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS) and sonicated using a Diagenode Bioruptor for three 10-minute rounds using pulsing settings (30 s ON; 1 min OFF). 10 μg of sonicated chromatin was then incubated overnight at 4°C with 5 μg of Flag antibody conjugated to magnetic beads. Following the IP, beads were washed twice with RIPA buffer (50mM Tris-HCl pH8, 150 mM NaCl, 2mM EDTA, 1% NP-40, 0.1% Na-deocycholate, 0.1% SDS), low salt buffer (20mM Tris pH 8.1, 150mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% SDS), high salt buffer (20mM Tris pH 8.1, 500mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% SDS), LiCl buffer (10mM Tris pH 8.1, 250mM LiCl, 1mM EDTA, 1% Na-deoxycholate, 1% NP-40), and 1X TE. Finally, DNA was extracted by reverse crosslinking at 60°C overnight with proteinase K (20ug/μL) and 1% SDS followed by phenol:chloroform:isoamyl alcohol purification and ethanol precipitation. All protocols for Illumina/Solexa sequencing library preparation, sequencing, and quality control were performed as recommended by Illumina, with the minor modification of limiting the PCR amplification step to 10 cycles and sequenced using single-end 50 bp reactions on a HiSeq4000.

### RNA-seq {#sec4.4.14}

Total RNA was purified by RNeasy Minikit (QIAGEN) according to the manufacturer's manual. RNA concentration was determined using Nanodrop, and 500 ng of total RNA was used for library construction using the KAPA Stranded mRNA-seq Kit. Sequencing was performed on Illumina HiSeq 2500 machines with 125 bp pair-end mode.

### Microarray analysis {#sec4.4.15}

*Dpf2*^*fl/fl*^ ESCs were treated with ethanol or 4-OHT for 48 hours before the induction of EBs formation. cRNA samples for global gene expression analyses were prepared with the linear TotalPrep RNA Amplification Kit (Ambion). Hybridizations on mouse-8 V2 chips (Illumina) were carried out as recommended by the manufacturer.

### Circularized Chromosome Conformation Capture (4C-seq) {#sec4.4.16}

4C experiments were performed on *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs using two 4-cutter DNA restriction enzymes. The experiments were carried out in two technical replicates, where around 10 million cells per biological sample were used. Cells were cross-linked with 1% formaldehyde for 10 minutes followed by cell lysis and nuclei isolation. The resulting nuclei were enzymatically digested with 1 μL/μg of fast digest MboI (Thermo Fisher Scientific) for 4.5 hours at 37°C. Subsequently, the material was ligated with 12 Weiss units of T4 DNA ligase (New England Biolabs) for 4.5 hours at 16°C. The ligation products were then purified using phenol-chloroform-isoamyl alcohol followed by precipitation with ethanol. Subsequently the purified DNA was subjected to secondary digestion with 1 μL/μg of Csp6I (Thermo Fisher Scientific) for 2 hours at 37°C. The digested DNA was then ligated with 12 Weiss units of T4 DNA ligase (New England Biolabs) for 4.5 hours at 16°C to generate circularized chimeric DNA, which was ethanol precipitated and cleaned using NucleoSpin gDNA Clean-Up (Macherey-Nagel) silica-membrane columns. The reading primer was designed for a 229bp region downstream of the TSS of *Tbx3* gene and the amplification was carried out using Expand Long Template PCR System (Roche). The sequence of the reading primer was 5′-TTGCACCCGTCTTCTTGATC-3′. The amplification reactions consisted of 100ng of DNA primed with 35 picomoles of each, forward and reverse primers, and 200 μM dNTPs. 1.75 U of a *Taq* and *Tgo* polymerase blend catalyzed the reaction. Thermal cycling was performed in GeneAmp PCR System 9700 (Applied Biosystems) following the protocol of initial denaturation at 94°C for 2 min, 29 cycles of 94°C for 10 s, 55°C for 1 min, 68°C for 3 min, and ended by the final elongation at 68°C for 5 min. Amplification products were directly used for DNA libraries preparation for Illumina single index, paired end sequencing using NextSeq 500 system (Illumina Inc.). The DNA libraries were prepared using KAPA HTP Library Preparation kit for Illumina Platforms following manufacturer's instructions entailing the end-repair of the amplified fragments, as well as A-tailing and TruSeq LT (Illumina Inc.) adaptor ligation. Prepared DNA libraries were purified and subjected for sequencing. 4C-seq was done in replicates.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Statistics {#sec4.5.1}

RNA-seq and ChIP-seq raw data are discrete count-based data, which follow negative binomial or Poisson distribution ([@bib28], [@bib27]), and no additional methods were used to determine whether the data met assumptions of the statistical approach. The experiments in [Figures 2](#fig2){ref-type="fig"}C and 2D and [S1](#mmc1){ref-type="supplementary-material"}A were performed once with two independent Dpf2 mutant ESC clones; all other experiments were performed three times or more. In all Figures, n = number of biological replicates or number of clones. All q-PCR data represent the mean of three technical replicates. All error bars represent standard deviation (SD). The Student's t test (unpaired, two-sided) was used to determine the significance of changes in the qPCR using Microsoft Excel. ^∗^ indicates p \< 0.05, ^∗∗^ p \< 0.01, ^∗∗∗^ \< 0.001. For all other statistics tests, they were specified and performed using indicated bioinformatics software described below in this section.

### Mass spectrometry analysis {#sec4.5.2}

Raw files were processed with the Proteome Discover 1.4 pipeline (Thermo Fisher Scientific). Database searches were performed with Mascot 2.5 (Matrix Science) against the mouse SwissProt database (v. January 2015). The search parameters were: trypsin/P with a maximum of 2 missed cleavages, 10 ppm mass tolerance for MS, 0.5 Da tolerance for MS/MS, with variable modifications of carbamidomethyl (C), N-acetylation (protein N-term), deamidation (NQ), formyl (N-term), oxidation (M), and Gln- \> pyro-Glu (N-term Q). Database search results were refined through processing with Mascot Percolator. Protein identification required at least one high-confidence peptide (FDR \< 1%). External contaminants (keratins, albumin, casein, immunoglobulins and TEV protease) were removed before further analysis. Protein lists from DPF2-FTAP experiments were compared to beta-gal-FTAP controls. High confidence DPF2 interactors were identified as those solely in DPF2-FTAP experiments, or with at least 3 times more sequences in DPF2-FTAP than in control experiments. We report these high confidence interactors identified by more than one peptide in at least one replicate in [Table S1](#mmc2){ref-type="supplementary-material"}.

### Data analysis {#sec4.5.3}

For ChIP-seq data, reads were mapped to the mouse mm9 reference genome using bowtie version 1.1.1 ([@bib24]) with -m 1 flag, which only allows uniquely mapped reads to be considered in the downstream analysis. Peaks were called using Macs2 (version 2.1.0.20151222)\_([@bib42]) with--nomodel--extsize 200 -q 0.01 flags. Two biological replicates were performed per experiment, and only peaks that were present in both replicates were considered. *De novo* Motif discovery was done using findMotifsGenome.pl from the HOMER suite ([@bib15]) (version 4.8) on the narrowPeak files returned from Macs2. For the analysis of peak overlap between different factors, intersectBed from the bedtools suite ([@bib32]) was used, and overlapping peaks were defined as two peaks with at least 1 bp overlap. For differential levels of H3K27ac and differential binding by OCT4 or BRG1 in *Dpf2*^*fl/fl*^ and *Dpf2*^*−/−*^ ESCs, a union peak set was created first between wild-type and knockout ChIP-seq samples using mergeBed from the bedtools suite. Briefly, the narrowPeak files from wild-type and knockout ESCs were merged if they had at least 1 bp overlap. The number of mapped reads from each condition was counted on each of the union peaks using coverageBed from the bedtools suite. The number of reads of each union peak was normalized by the sequencing depth of different samples. For each union peak of OCT4, BRG1 and H3K27ac, we assigned differentially bound genomic locations if at least 2-fold difference between the wild-type and knockout samples was observed.

For RNA-seq data analysis, reads were mapped to the mouse mm9 reference genome with Tophat ([@bib35]) version 2.0.13 and supplied with gene annotation from RefSeq. Gene expression was quantified by cuffquant, and differential gene expression test was performed using cuffdiff. Both cuffquant and cuffdiff were from the cufflinks package ([@bib36]) (version 2.2.1).

Microarray data analysis was done in BeadStudio and MS Excel.

### GO analysis {#sec4.5.4}

GO analysis for enriched biological processes was performed using Metascape (<http://metascape.org>) to find significantly enriched terms (P value ≤ 0.01).

### ChromHMM ESC states, TF enrichments and data visualization {#sec4.5.5}

Chromatin state segmentations for the ESCs were obtained from ([@bib10]). To calculate the enrichment of binding events in distinct chromatin states, we utilized the ChromHMM OverlapEnrichment function as previously described ([@bib10]). The enrichment score was calculated as the ratio between observed and expected overlap between the binding event of interest and chromatin state after accounting their relative size and the size of the mouse genome.

To produce the heatmaps in Figures 3F/H, 4C/G/I and S3D/E we aligned the given feature (such as peaks of DPF2, BRG1 or EED) at their summit and tiled the flanking up- and downstream regions within ± 2kb in 100bp bins. For each location, we calculated RPKM values over all 100bp bins by using the number of sequencing reads that overlapped with each bin after extension by 50bp in the direction of the alignment. To normalize to the input control, we computed at each corresponding bin a log~2~ input-normalized RPKM value as log~2~(RPKM~FOREGROUND~) - log~2~(RPKM~Input~). For visualization in figures, each 100 bp bin was displayed with JavaTreeview. All metaplots were produced by computing the average input-normalized RPKM value for each 100bp bin across all locations in the given set. In Figure S4D, the fold-enrichment of Dpf2 in the vicinity (+/− 20Kb of the TSS) of up- and downregulated genes at sites exhibiting H3K27ac, Oct4 or Brg1 binding gain or reduction was calculated with the following formulas:(% Upregulated Dpf2 bound genes within region of interest) / (%All Dpf2 bound genes within regions of interest) and (% Downregulated Dpf2 bound genes within region of interest)/ (%All Dpf2 bound genes within regions of interest).

### TF clustering and pairwise comparisons with optimal leaf ordering {#sec4.5.6}

K-means clustering was employed to identify constitutive and stage specific binding of DPF2 in ESCs and EBs in [Figures 5](#fig5){ref-type="fig"}A. To define these TF clusters, the genome was tiled into 500bp windows and the presence of TF peaks in each bin was determined. This procedure resulted in a vector of binary data for each TF reflecting its absence or presence within 500bp windows across the genome. The windows represented by these vectors were then clustered using R's k-means function applying the Hartigan-Wong method to obtain groups of windows exhibiting common combinatorial binding patterns across the genome.

In [Figure 3](#fig3){ref-type="fig"}E we applied complete linkage hierarchical clustering with optimal leaf ordering to cluster the enrichments of all pairs of TFs ([@bib1]). The pairwise enrichments at base-pair resolution were calculated as the observed overlap divided by the expected overlap based on the binomial background model that treats both transcription factors as independent:$${Enrichment}\left( {TF_{A},TF_{B}} \right) = \min\left( {\frac{100 + TF_{A} \cap TF_{B}}{100 + TF_{A} \ast {{TF_{B}}/G}},500} \right)$$- where the numerator is the size of the overlap between peaks of TF~A~ and TF~B~ and the denominator is the product between the total number of bp occupied by peaks of TF~A~ and TF~B~ divided by the size of the genome (G). The maximum enrichment was set to 500. TF datasets for TFs not generated at this study were obtained from Chronis et al., GEO: [GSE90895](ncbi-geo:GSE90895){#intref0025}.

### Circularized Chromosome Conformation Capture (4C) analysis {#sec4.5.7}

Resulting data were mapped with Bowtie 2 after trimming primer sequences. Duplicates and low quality reads were discarded. Counts for restriction enzyme fragments were generated using Bioconductor package FourCSeq ([@bib21]). Only the interactions that were supported by at least 16 read pairs (corresponding to FDR = 0.1) in both replicates were taken forward.

Data and Software Availability {#sec4.6}
------------------------------

The accession numbers for ChIP-seq, RNA-seq and 4C data are [E-MTAB-6165](array-express:E-MTAB-6165){#intref0030}, [E-MTAB-6166](array-express:E-MTAB-6166){#intref0035} and [E-MTAB-6167](array-express:E-MTAB-6167){#intref0040}, respectively on ArrayExpress. The proteomics data are available via ProteomeXchange with identifier PXD011806.
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